Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial.
Sophie Merrick, Annabelle South, Elena Frangou et al.
✦ AI-curated · Sources linked
In 30 seconds
This qualitative study explored the health-related quality of life (HRQoL) impacts of adjuvant immune checkpoint inhibitors (ICIs) in renal cell carcinoma patients from the RAMPART trial. Among 23 interviewed participants, findings revealed that chronic immune-related adverse events (irAEs) significantly affected daily functioning and mental health, with a focus on the duration of these effects rather than their severity.
Key findings
- Participants prioritized the duration and chronicity of irAEs over their severity in relation to HRQoL.
- Persistent toxicities like fatigue and diarrhoea disrupted daily functioning.
- Cognitive changes and emotional strain were frequently reported among participants.
- Supportive relationships and structured follow-up helped mitigate the burden of irAEs.
Why it matters
Understanding the nuanced impacts of chronic irAEs on HRQoL is crucial for clinicians to support patient decision-making and improve care strategies. This insight can guide the development of more effective management plans for patients undergoing ICI therapy.